{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:19:08Z","timestamp":1777349948188,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,8,29]],"date-time":"2013-08-29T00:00:00Z","timestamp":1377734400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s00125-013-3032-8","type":"journal-article","created":{"date-parts":[[2013,8,28]],"date-time":"2013-08-28T09:51:06Z","timestamp":1377683466000},"page":"2702-2712","source":"Crossref","is-referenced-by-count":14,"title":["Latanoprost effectively ameliorates glucose and lipid disorders in db\/db and ob\/ob mice"],"prefix":"10.1007","volume":"56","author":[{"given":"Gaihong","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,29]]},"reference":[{"key":"3032_CR1","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","volume":"27","author":"S Wild","year":"2004","unstructured":"Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047\u20131053","journal-title":"Diabetes Care"},{"key":"3032_CR2","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cell.2012.02.017","volume":"148","author":"VT Samuel","year":"2012","unstructured":"Samuel VT, Shulman GI (2012) Mechanisms for insulin resistance: common threads and missing links. Cell 148:852\u2013871","journal-title":"Cell"},{"key":"3032_CR3","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.cell.2005.11.026","volume":"123","author":"M Lehrke","year":"2005","unstructured":"Lehrke M, Lazar MA (2005) The many faces of PPARgamma. Cell 123:993\u2013999","journal-title":"Cell"},{"key":"3032_CR4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1172\/JCI10843","volume":"106","author":"JM Olefsky","year":"2000","unstructured":"Olefsky JM (2000) Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 106:467\u2013472","journal-title":"J Clin Invest"},{"key":"3032_CR5","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1001\/jama.298.10.1189","volume":"298","author":"S Singh","year":"2007","unstructured":"Singh S, Loke YK, Furberg CD (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298:1189\u20131195","journal-title":"JAMA"},{"key":"3032_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0739-7240(01)00117-5","volume":"22","author":"KL Houseknecht","year":"2002","unstructured":"Houseknecht KL, Cole BM, Steele PJ (2002) Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review. Domest Anim Endocrinol 22:1\u201323","journal-title":"Domest Anim Endocrinol"},{"key":"3032_CR7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1172\/JCI8538","volume":"105","author":"PD Miles","year":"2000","unstructured":"Miles PD, Barak Y, He W, Evans RM, Olefsky JM (2000) Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest 105:287\u2013292","journal-title":"J Clin Invest"},{"key":"3032_CR8","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1172\/JCI12864","volume":"108","author":"T Yamauchi","year":"2001","unstructured":"Yamauchi T, Waki H, Kamon J et al (2001) Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 108:1001\u20131013","journal-title":"J Clin Invest"},{"key":"3032_CR9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2004.12.003","volume":"1","author":"BB Kahn","year":"2005","unstructured":"Kahn BB, Alquier T, Carling D, Hardie DG (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1:15\u201325","journal-title":"Cell Metab"},{"key":"3032_CR10","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/01.RES.0000256090.42690.05","volume":"100","author":"MC Towler","year":"2007","unstructured":"Towler MC, Hardie DG (2007) AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100:328\u2013341","journal-title":"Circ Res"},{"key":"3032_CR11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.molmed.2008.09.007","volume":"14","author":"R Lage","year":"2008","unstructured":"Lage R, Dieguez C, Vidal-Puig A, Lopez M (2008) AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med 14:539\u2013549","journal-title":"Trends Mol Med"},{"key":"3032_CR12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.cmet.2009.03.012","volume":"9","author":"BB Zhang","year":"2009","unstructured":"Zhang BB, Zhou G, Li C (2009) AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 9:407\u2013416","journal-title":"Cell Metab"},{"key":"3032_CR13","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/448645a","volume":"448","author":"CR Chong","year":"2007","unstructured":"Chong CR, Sullivan DJ Jr (2007) New uses for old drugs. Nature 448:645\u2013646","journal-title":"Nature"},{"key":"3032_CR14","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/414821a","volume":"414","author":"DE Moller","year":"2001","unstructured":"Moller DE (2001) New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414:821\u2013827","journal-title":"Nature"},{"issue":"Pt 1","key":"3032_CR15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/eye.1999.6","volume":"13","author":"M McKibbin","year":"1999","unstructured":"McKibbin M, Menage MJ (1999) The effect of once-daily latanoprost on intraocular pressure and pulsatile ocular blood flow in normal tension glaucoma. Eye (Lond) 13(Pt 1):31\u201334","journal-title":"Eye (Lond)"},{"key":"3032_CR16","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s10384-011-0075-6","volume":"55","author":"M Aihara","year":"2011","unstructured":"Aihara M, Shirato S, Sakata R (2011) Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost. Jpn J Ophthalmol 55:600\u2013604","journal-title":"Jpn J Ophthalmol"},{"key":"3032_CR17","doi-asserted-by":"crossref","first-page":"e24224","DOI":"10.1371\/journal.pone.0024224","volume":"6","author":"X Tang","year":"2011","unstructured":"Tang X, Zhuang J, Chen J et al (2011) Arctigenin efficiently enhanced sedentary mice treadmill endurance. PLoS One 6:e24224","journal-title":"PLoS One"},{"key":"3032_CR18","doi-asserted-by":"crossref","first-page":"e31811","DOI":"10.1371\/journal.pone.0031811","volume":"7","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Zhang H, Yao XG et al (2012) (+)-Rutamarin as a dual inducer of both GLUT4 translocation and expression efficiently ameliorates glucose homeostasis in insulin-resistant mice. PLoS One 7:e31811","journal-title":"PLoS One"},{"key":"3032_CR19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bbalip.2011.04.003","volume":"1821","author":"E Perez","year":"2012","unstructured":"Perez E, Bourguet W, Gronemeyer H, de Lera AR (2012) Modulation of RXR function through ligand design. Biochim Biophys Acta Mol Cell Biol Lipids 1821:57\u201369","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"3032_CR20","doi-asserted-by":"crossref","first-page":"15813","DOI":"10.1074\/jbc.M201075200","volume":"277","author":"H Tokumitsu","year":"2002","unstructured":"Tokumitsu H, Inuzuka H, Ishikawa Y, Ikeda M, Saji I, Kobayashi R (2002) STO-609, a specific inhibitor of the Ca2+\/calmodulin-dependent protein kinase kinase. J Biol Chem 277:15813\u201315818","journal-title":"J Biol Chem"},{"key":"3032_CR21","first-page":"1278","volume":"290","author":"BW Griffin","year":"1999","unstructured":"Griffin BW, Klimko P, Crider JY, Sharif NA (1999) AL-8810: a novel prostaglandin F2 alpha analog with selective antagonist effects at the prostaglandin F2 alpha (FP) receptor. J Pharmacol Exp Ther 290:1278\u20131284","journal-title":"J Pharmacol Exp Ther"},{"key":"3032_CR22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1743-7075-3-31","volume":"3","author":"S Giri","year":"2006","unstructured":"Giri S, Rattan R, Haq E et al (2006) AICAR inhibits adipocyte differentiation in 3T3L1 and restores metabolic alterations in diet-induced obesity mice model. Nutr Metab (Lond) 3:31","journal-title":"Nutr Metab (Lond)"},{"key":"3032_CR23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cmet.2006.07.001","volume":"4","author":"SR Farmer","year":"2006","unstructured":"Farmer SR (2006) Transcriptional control of adipocyte formation. Cell Metab 4:263\u2013273","journal-title":"Cell Metab"},{"key":"3032_CR24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.abb.2008.07.029","volume":"479","author":"M Nam","year":"2008","unstructured":"Nam M, Lee WH, Bae EJ, Kim SG (2008) Compound C inhibits clonal expansion of preadipocytes by increasing p21 level irrespectively of AMPK inhibition. Arch Biochem Biophys 479:74\u201381","journal-title":"Arch Biochem Biophys"},{"key":"3032_CR25","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrm2391","volume":"9","author":"A Guilherme","year":"2008","unstructured":"Guilherme A, Virbasius JV, Puri V, Czech MP (2008) Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 9:367\u2013377","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3032_CR26","doi-asserted-by":"crossref","first-page":"16309","DOI":"10.1073\/pnas.222657499","volume":"99","author":"E Tomas","year":"2002","unstructured":"Tomas E, Tsao TS, Saha AK et al (2002) Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A 99:16309\u201316313","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3032_CR27","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.2337\/db05-1606","volume":"55","author":"YI Kim","year":"2006","unstructured":"Kim YI, Lee FN, Choi WS, Lee S, Youn JH (2006) Insulin regulation of skeletal muscle PDK4 mRNA expression is impaired in acute insulin-resistant states. Diabetes 55:2311\u20132317","journal-title":"Diabetes"},{"key":"3032_CR28","doi-asserted-by":"crossref","first-page":"14297","DOI":"10.1073\/pnas.2335926100","volume":"100","author":"MW Sleeman","year":"2003","unstructured":"Sleeman MW, Garcia K, Liu R et al (2003) Ciliary neurotrophic factor improves diabetic parameters and hepatic steatosis and increases basal metabolic rate in db\/db mice. Proc Natl Acad Sci U S A 100:14297\u201314302","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3032_CR29","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.2337\/diabetes.54.5.1459","volume":"54","author":"HKR Karlsson","year":"2005","unstructured":"Karlsson HKR, Hallsten K, Bjornholm M et al (2005) Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes\u2014a randomized controlled study. Diabetes 54:1459\u20131467","journal-title":"Diabetes"},{"key":"3032_CR30","doi-asserted-by":"crossref","first-page":"19970","DOI":"10.1074\/jbc.M402165200","volume":"279","author":"EK Kim","year":"2004","unstructured":"Kim EK, Miller I, Aja S et al (2004) C75, a fatty acid synthase inhibitor, reduces food intake via hypothalamic AMP-activated protein kinase. J Biol Chem 279:19970\u201319976","journal-title":"J Biol Chem"},{"key":"3032_CR31","doi-asserted-by":"crossref","first-page":"32571","DOI":"10.1074\/jbc.M201692200","volume":"277","author":"H Park","year":"2002","unstructured":"Park H, Kaushik VK, Constant S et al (2002) Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J Biol Chem 277:32571\u201332577","journal-title":"J Biol Chem"},{"key":"3032_CR32","doi-asserted-by":"crossref","first-page":"7522","DOI":"10.1073\/pnas.121164498","volume":"98","author":"JK Kim","year":"2001","unstructured":"Kim JK, Fillmore JJ, Chen Y et al (2001) Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 98:7522\u20137527","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3032_CR33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/15216540400009968","volume":"56","author":"JT Tansey","year":"2004","unstructured":"Tansey JT, Sztalryd C, Hlavin EM, Kimmel AR, Londos C (2004) The central role of perilipin a in lipid metabolism and adipocyte lipolysis. IUBMB Life 56:379\u2013385","journal-title":"IUBMB Life"},{"key":"3032_CR34","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/oby.2007.206","volume":"15","author":"E Warensjo","year":"2007","unstructured":"Warensjo E, Ingelsson E, Lundmark P et al (2007) Polymorphisms in the SCD1 gene: associations with body fat distribution and insulin sensitivity. Obesity (Silver Spring) 15:1732\u20131740","journal-title":"Obesity (Silver Spring)"},{"key":"3032_CR35","doi-asserted-by":"crossref","first-page":"E46","DOI":"10.1152\/ajpendo.00536.2007","volume":"295","author":"NH Jeoung","year":"2008","unstructured":"Jeoung NH, Harris RA (2008) Pyruvate dehydrogenase kinase-4 deficiency lowers blood glucose and improves glucose tolerance in diet-induced obese mice. Am J Physiol Endocrinol Metab 295:E46\u2013E54","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"3032_CR36","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.ijo.0802943","volume":"29","author":"MC Carmona","year":"2005","unstructured":"Carmona MC, Louche K, Nibbelink M et al (2005) Fenofibrate prevents Rosiglitazone-induced body weight gain in ob\/ob mice. Int J Obes (Lond) 29:864\u2013871","journal-title":"Int J Obes (Lond)"},{"key":"3032_CR37","doi-asserted-by":"crossref","first-page":"34268","DOI":"10.1074\/jbc.M300043200","volume":"278","author":"O Gavrilova","year":"2003","unstructured":"Gavrilova O, Haluzik M, Matsusue K et al (2003) Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 278:34268\u201334276","journal-title":"J Biol Chem"},{"key":"3032_CR38","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/79839","volume":"26","author":"D Altshuler","year":"2000","unstructured":"Altshuler D, Hirschhorn JN, Klannemark M et al (2000) The common PPAR gamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76\u201380","journal-title":"Nat Genet"},{"key":"3032_CR39","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1074-5521(00)00036-3","volume":"7","author":"M Herdick","year":"2000","unstructured":"Herdick M, Steinmeyer A, Carlberg C (2000) Carboxylic ester antagonists of 1alpha,25-dihydroxyvitamin D(3) show cell-specific actions. Chem Biol 7:885\u2013894","journal-title":"Chem Biol"},{"key":"3032_CR40","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1124\/mol.59.6.1478","volume":"59","author":"A Toell","year":"2001","unstructured":"Toell A, Gonzalez MM, Ruf D, Steinmeyer A, Ishizuka S, Carlberg C (2001) Different molecular mechanisms of vitamin D(3) receptor antagonists. Mol Pharmacol 59:1478\u20131485","journal-title":"Mol Pharmacol"},{"key":"3032_CR41","doi-asserted-by":"crossref","first-page":"19649","DOI":"10.1074\/jbc.M200743200","volume":"277","author":"G Lee","year":"2002","unstructured":"Lee G, Elwood F, McNally J et al (2002) T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem 277:19649\u201319657","journal-title":"J Biol Chem"},{"key":"3032_CR42","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1074\/jbc.M110.166215","volume":"286","author":"HT Zhang","year":"2011","unstructured":"Zhang HT, Zhou R, Li L et al (2011) Danthron functions as a retinoic X receptor antagonist by stabilizing tetramers of the receptor. J Biol Chem 286:1868\u20131875","journal-title":"J Biol Chem"},{"key":"3032_CR43","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.1074\/jbc.272.4.2346","volume":"272","author":"R Mukherjee","year":"1997","unstructured":"Mukherjee R, Jow L, Croston GE, Paterniti JR Jr (1997) Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 272:8071\u20138076","journal-title":"J Biol Chem"},{"key":"3032_CR44","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s00347-002-0613-1","volume":"99","author":"T Schlote","year":"2002","unstructured":"Schlote T (2002) Side-effects and risk profile of latanoprost 0.005% (Xalatan). Ophthalmologe 99:724\u2013729","journal-title":"Ophthalmologe"},{"key":"3032_CR45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10384-010-0904-z","volume":"55","author":"J Park","year":"2011","unstructured":"Park J, Cho HK, Moon JI (2011) Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol 55:22\u201327","journal-title":"Jpn J Ophthalmol"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-013-3032-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-013-3032-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-013-3032-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T06:16:37Z","timestamp":1563776197000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-013-3032-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,29]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["3032"],"URL":"https:\/\/doi.org\/10.1007\/s00125-013-3032-8","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,29]]}}}